Top-5 Cardiovascular Trial Site - Southeast US
Seven active Phase 1-3 cardiovascular trials. 20+ pharma sponsors including Alnylam, Pfizer, and Pharmacosmos. GCSA-certified. Led by the U.S. TAVR pioneer. Sponsors get audit-ready data on schedule. Patients get tomorrow's standard of care, today, at no cost.
Led by Dr. William O'Neill -- pioneer of TAVR in the United States
7
Active Trials Now
20+
Pharma Partners
Top 5
CV Site in Southeast US
15+
Years of Experience
Leadership
Performed the first TAVR in the United States — now leading clinical trial science at Amavita Research.
Our leadership team combines pioneering interventional expertise with proven clinical research execution.
Chief Medical OfficerChief Medical Officer & Senior Principal Investigator
Internationally renowned interventional cardiologist and pioneer in structural heart disease. Medical Director, Center for Structural Heart Disease, Henry Ford Hospital · Chief Medical Advisor, CardioElite™. Performed the first TAVR in the United States and served as National Principal Investigator for the Edwards PARTNER, Protect II, and Protect IV trials.
Founder and Lead Investigator
Harvard-trained interventional cardiologist with 15+ years of experience and 25+ clinical research trials, including pivotal work helping develop the Trans-Caval TAVR approach and serving as Worldwide PI on the Percutaneous Mitral Valve Annuloplasty trial. Founder and CEO of amavita Heart and Vascular Health® — the largest independent cardiovascular practice in South Florida.
Chief Executive Officer (CEO)
Drives growth strategy, sponsor relationships, and cross-border trial operations at Amavita Research. CEO of bioaccess® with 20+ years scaling clinical research operations across Latin America and the United States. Former Ambassador of IAOCR / GCSA Americas.
Sister Organization
Amavita Research's sister organization, bioaccess®, is a first-in-human CRO operating across 10 Latin American markets, with 50+ delivered FIH programs since 2010. Under shared leadership, sponsors can design integrated US + Latin America trial programs — a first-in-human or Phase 1 cohort in Latin America via bioaccess®, with expansion at Amavita Research's Miami site — coordinated through a single team.
Affiliated ASCOur Surgical Center Advantage
The only ambulatory surgery center of its kind in South Florida.
Amavita Research patients and sponsor trials have direct access to Advanced Cardiovascular of Miami — South Florida's only dedicated cardiovascular and interventional-radiology ambulatory surgery center. A next-generation cath lab built for advanced same-day procedures.
9408 SW 87th Ave., Suite 303, Miami, FL 33176
Active Studies
Investigating tomorrow's standards of care across cardiology, hypertension, and vascular medicine.
Heart Failure with Preserved Ejection Fraction (HFpEF)
VS-041-102
A safety, tolerability, and biomarker trial of VS-041 in participants with Heart Failure with Preserved Ejection Fraction. Amavita Research Services is an enrolling site under Medpace clinical trial agreement, with Dr. Pedro Martinez-Clark as Principal Investigator.
Eligibility & detailsHeart Failure with Preserved Ejection Fraction (HFpEF)
C4921003
Phase 2 study of PF-07328948, an oral branched-chain ketoacid dehydrogenase (BCKD) kinase inhibitor, in adults with heart failure. The trial evaluates the metabolic pathway that branched-chain amino acid catabolism plays in cardiac function in HFpEF.
Eligibility & detailsHeart failure with mid-range or preserved ejection fraction and systemic inflammation
EX6018-4915
A Phase 3 randomized, placebo-controlled trial evaluating ziltivekimab, a fully human monoclonal antibody targeting interleukin-6, in patients with heart failure and systemic inflammation. Amavita Research Services is an enrolling site, with Dr. Pedro Martinez-Clark as Principal Investigator.
Eligibility & detailsHeart Failure with Reduced Ejection Fraction (HFrEF)
Phase 2B study of AC01, an oral ghrelin receptor agonist, administered over 12 weeks in patients with chronic advanced heart failure with reduced ejection fraction (HFrEF). The trial is in site start-up.
Eligibility & detailsIron-Deficiency Chronic Heart Failure
P-Monofer-CHF-02
Phase 3 trial of ferric derisomaltose (intravenous iron) versus no intravenous iron in iron-deficient subjects with symptomatic chronic heart failure. ICONIC-HF measures the impact of IV iron supplementation on HF outcomes.
Eligibility & detailsPeripheral Artery Disease
AVA-CL-5000
The GREAT Trial evaluates the Golazo® Peripheral Atherectomy System for safe and effective atherectomy in patients with peripheral artery disease. Phase: device IDE study.
Eligibility & detailsHypertension with Cardiovascular Risk
ALN-AGT01-008
Phase 3 study of zilebesiran in patients with hypertension not adequately controlled and with either established cardiovascular disease or high risk for cardiovascular disease. Zilebesiran is a subcutaneous RNAi therapeutic targeting hepatic angiotensinogen.
Eligibility & detailsTrusted by leading sponsors
20+ pharmaceutical, biotech, and device partners — across active and completed trials
For Patients
For Sponsors
FAQ
Quick answers about clinical trials, leadership, location, and what participation involves at Amavita Research.
Insights
Plain-language education on clinical trials, conditions, and procedures — written for patients and partners.
For Patients
From the first phone call through the final follow-up visit, here is a step-by-step look at what participating in a cardiovascular clinical trial actually involves.
Read moreClinical Research Basics
Drug clinical trials are organized into phases. Each one answers different safety and effectiveness questions. Here is what each phase is for, in plain language.
Read moreClinical Research Basics
First-in-human (FIH) trials are the first time a new therapy is studied in people. Here is how protocols, oversight, and site experience combine to keep participants safe.
Read moreWhether you are a patient seeking new treatment options or a sponsor planning your next study, our team is ready to help.
